11:48 AM EDT, 07/13/2026 (MT Newswires) -- Zelluna (ZLNA.OL) dosed the first patient in the phase 1 clinical trial evaluating ZI-MA4-1, its lead T-cell receptor-based natural killer cell therapy candidate. The study, conducted in the UK, is evaluating the safety, tolerability, and preliminary anti-tumor activity of ZI-MA4-1 in patients with advanced MAGE-A4-positive solid tumors, according to a Monday filing. The Norwegian biopharmaceutical company said it is on track to come up with initial clinical data halfway through the year.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.